Hint mode is switched on Switch off
For swift navigation between sections

Morphic Holding
LEI 549300RWWOUFLHTY1224

PDF download

Choose all Reset all
Download Cancel
Organization name
Morphic Holding, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014.

Awards

News

04/06/2024 Morphic Holding: Submission Of Matters To A Vote Of Security Holders
25/04/2024 Morphic Holding: Entry Into A Material Definitive Agreement, Termination Of A Material Definitive Agreement, Financial Statements And Exhibits
12/03/2024 Morphic Holding: Regulation Fd Disclosure, Financial Statements And Exhibits
22/02/2024 Morphic Holding: Results Of Operations And Financial Condition, Financial Statements And Exhibits
10/01/2024 Morphic Holding: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2024
I q eng
II q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300RWWOUFLHTY1224
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001679363
  • EIN
    47-3878772
Registration is required to get access.